By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Selexis SA 

Chemin des Aulx, 14

Plan les Ouates   Geneva  1228   Switzerland
Phone: 41-0.-22-308-93-60 Fax:


Key Statistics

Ownership: Private

Web Site: Selexis SA


Start Up

Company News
Selexis SA Announces Commercial License Agreement With Takeda (TKPYY) For The Development Of Fusion Proteins 6/27/2017 6:34:32 AM
JSR Life Sciences Agrees To Acquire Pioneering Cell Line Developer Selexis SA And Integrate Selexis With KBI BioPharma 6/14/2017 6:48:30 AM
Selexis SA And TeneoBio, Inc.Team Up To Advance The Development Of Uniabs Targeting Cancer 6/12/2017 11:18:48 AM
Merck KGaA (MKGAF.PK), Darmstadt, Germany Licenses Selexis SA Suretechnology Platform For Immuno-Oncology Antibody Program 5/30/2017 9:11:29 AM
Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement To Further Advance Development Of OSE's Interleukin Receptor 7 Antagonist 5/23/2017 2:02:01 PM
Selexis SA Opens New World-Class Laboratory Facility And Corporate Headquarters In Geneva, Switzerland 5/12/2017 6:46:22 AM
Selexis SA Announces Launch Of Novel Cell Selection Platform Designed To Help Advance Difficult-To-Express Protein Therapeutics To The Clinic 3/20/2017 6:35:23 AM
Selexis SA Announces Participation At Several Upcoming Industry Conferences 3/14/2017 8:28:50 AM
Selexis SA Inks Agreement For Applications In Cancer And Infectious Disease 2/21/2017 8:30:25 AM
Selexis SA And OSE Immunotherapeutics Collaborate To Advance Development Of Immunotherapies For Cancer And Autoimmune Diseases 11/16/2016 10:36:03 AM